Use of atypical antipsychotics in the elderly: A clinical review

Clinical Interventions in Aging

Volumn 9, Issue , 2014, Pages 1363-1373

  Gareri, Pietro ^a   Segura García, Cristina ^b   Manfredi, Valeria Graziella Laura ^a   Bruni, Antonella ^b   Ciambrone, Paola ^b   Cerminara, Gregorio ^b   De Sarro, Giovambattista ^b   De Fazio, Pasquale ^b  

^a Operative Unit Elderly Health Care   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Atypical antipsychotics; Dementia; Elderly; Mood disorders; Psychosis; Side effects

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; AMISULPRIDE; ARIPIPRAZOLE; ASENAPINE; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINERGIC RECEPTOR; CLOZAPINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; HALOPERIDOL; HISTAMINE H1 RECEPTOR; MUSCARINIC RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PERPHENAZINE; PLACEBO; PROLACTIN; QUETIAPINE; RISPERIDONE; SEROTONIN 2 RECEPTOR; SEROTONIN 7 RECEPTOR; SERTINDOLE; UNINDEXED DRUG; ZIPRASIDONE;

ACUTE HEART INFARCTION; AGRANULOCYTOSIS; ALZHEIMER DISEASE; AMENORRHEA; ANTICHOLINERGIC EFFECT; ANTICHOLINERGIC SYNDROME; ANTIDEPRESSANT ACTIVITY; ASPIRATION PNEUMONIA; BEHAVIOR DISORDER; BINDING AFFINITY; BIPOLAR DISORDER; CARDIOMETABOLIC RISK; CEREBROVASCULAR DISEASE; CHOLINERGIC TRANSMISSION; CLINICAL TRIAL (TOPIC); CONSTIPATION; DEEP VEIN THROMBOSIS; DEMENTIA; DEPRESSION; DIABETES MELLITUS; DOPAMINERGIC TRANSMISSION; DRUG BIOAVAILABILITY; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DYSLIPIDEMIA; DYSPHAGIA; DYSTHYMIA; ENDOCRINE DISEASE; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; GALACTORRHEA; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HEART INFARCTION; HEMATOLOGIC DISEASE; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPOTENSION; INFECTION; INTERSTITIAL NEPHRITIS; LIVER DISEASE; MOOD DISORDER; MOTOR DYSFUNCTION; MYOCARDITIS; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; NEUTROPENIA; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PERIPHERAL EDEMA; POLYSEROSITIS; PSYCHIATRY; PSYCHOSIS; QT PROLONGATION; RASH; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEIZURE; SOMNOLENCE; SUDDEN DEATH; TARDIVE DYSKINESIA; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT GAIN; AGED; MENTAL DISORDERS;

AGED; ANTIPSYCHOTIC AGENTS; HUMANS; MENTAL DISORDERS;

EID: 84907361110     PISSN: 11769092     EISSN: 11781998     Source Type: Journal    
DOI: 10.2147/CIA.S63942     Document Type: Review

References (82)

1. Aarsland D, Larsen JP, Lim NG, Tandberg E. Olanzapine for psychosis in patients with Parkinson's disease with and without dementia. J Neuropsychiatry Clin Neurosci. 1999;11(3):392-394.
2. Alexopoulos GS, Streim J, Carpenter D, Docherty JP. Using antipsychotic agents in older patients. J Clin Psychiatry. 2004;65(Suppl 2):5-99.
3. Ashcroft DM, Frischer M, Lockett J, Chapman SR. Variations in prescribing atypical antipsychotic drugs in primary care: cross-sectional study. Pharmacoepidemiol Drug Saf. 2002;11(4):285-289.
4. Barak Y, Shamir E, Weizman R. Would a switch from typical antipsychotics to risperidone be beneficial for elderly schizophrenic patients? A naturalistic, long-term, retrospective, comparative study. J Clin Psychopharmacol. 2002;22(2):115-120.
5. Meltzer HY. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology. 1999;21(Suppl 2):106S-115S.
6. Shin JY, Choi NK, Jung SY, Lee J, Kwon JS, Park BJ. Risk of ischemic stroke with the use of risperidone, quetiapine and olanzapine in elderly patients: a population-based, case-crossover study. J Psychopharmacol. 2013;27(7):638-644.
7. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009; 360(3):225-235.
8. Wetzel H, Wiesner J, Hiemke C, Benkert O. Acute antagonism of dopamine D2-like receptors by amisulpride: effects on hormone secretion in healthy volunteers. J Psychiatr Res. 1994;28(5):461-473.
9. Xiberas X, Martinot JL, Mallet L, et al. In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia. J Clin Psychopharmacol. 2001;21(2):207-214.
10. Gareri P, De Fazio P, Stilo M, Ferreri G, De Sarro G. Conventional and atypical antipsychotics in the elderly: a review. Clin Drug Investig. 2003;23(5):287-322.
11. Schoemaker H, Claustre Y, Fage D, et al. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther. 1997;280(1):83-97.
12. Abbas AI, Hedlund PB, Huang XP, Tran TB, Meltzer HY, Roth BL. Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology (Berl). 2009;205(1):119-128.
13. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002;47(1):27-38.
14. Stahl SM. Antipsychotic polypharmacy, part 1: therapeutic option or dirty little secret? J Clin Psychiatry. 1999;60(7):425-426.
15. Gareri P, De Fazio P, Russo E, Marigliano N, De Fazio S, De Sarro G. The safety of clozapine in the elderly. Expert Opin Drug Saf. 2008;7(5): 525-538.
16. Khan AJ, Preskorn SH. Examining concentration-dependent toxicity of clozapine: role of therapeutic drug monitoring. J Psychiatr Pract. 2005;11(5):289-301.
17. Deberdt W, Dysken MW, Rappaport SA, et al. Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia. Am J Geriatr Psychiatry. 2005;13(8):722-730.
18. Burke AD, Tariot PN. Atypical antipsychotics in the elderly: a review of therapeutic trends and clinical outcomes. Expert Opin Pharmacother. 2009;10(15):2407-2414.
19. Jeste DV, Blazer D, Casey D, et al. ACNP White Paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology. 2008;33(5):957-970.
20. Green B. Focus on quetiapine. Curr Med Res Opin. 1999;15(3): 145-151.
21. Kohen I, Lester PE, Lam S. Antipsychotic treatments for the elderly: efficacy and safety of aripiprazole. Neuropsychiatr Dis Treat. 2010;6: 47-58.
22. Markowitz JS, Brown CS, Moore TR. Atypical antipsychotics. Part I: pharmacology, pharmacokinetics, and efficacy. Ann Pharmacother. 1999;33(1):73-85.
23. Brook S, Lucey JV, Gunn KP. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. J Clin Psychiatry. 2000;61(12):933-941.
24. Kech PE Jr, McElroy SL, Arnold LM. Ziprasidone: a new atypical antipsychotic. Expert Opin Pharmacother. 2001;2(6):1033-1042.
25. Madhusoodanan S, Zaveri D. Paliperidone use in the elderly. Curr Drug Saf. 2010;5(2):149-152.
26. Tauscher J, Kufferle B, Asenbaum S, Tauscher-Wisniewski S, Kasper S. Striatal dopamine-2 receptor occupancy as measured with (123 I)iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol. Psychopharmacology (Berl). 2002;162(1):42-49.
27. Shahid M, Walker GB, Zorn SH, Wong EH. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009;23(1):65-73.
28. Hermann RC, Yang D, Ettner SL, Marcus SC, Yoon C, Abraham M. Prescription of antipsychotic drugs by office-based physicians in the United States, 1989-1997. Psychiatr Serv. 2002;53(4):425-430.
29. Jeste DV, Eastham JH, Lohr JB. Treatment of behavioral disorders and psychosis. In: Salzman C, editor. Clinical Geriatric Psychopharmacology. Baltimore, MD: Williams and Wilkins; 1998:106-149.
30. Trifiro G, Spina E, Brignoli O, Sessa E, Caputi AP, Mazzaglia G. Antipsychotic prescribing pattern among Italian general practitioners: a population-based study during the years 1999-2002. Eur J Clin Pharmacol. 2005;61(1):47-53.
31. Crismon L, Argo TR, Buckley PF. Schizophrenia. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey M, editors. Pharmacotherapy: A Pathophysiologic Approach. 7th ed. New York, NY: McGraw-Hill; 2008:1099-1123.
32. Singh D, O'Connor DW. Efficacy and safety of risperidone long-acting injection in elderly people with schizophrenia. Clin Interv Aging. 2009;4:351-355.
33. Davidson M, Harvey PD, Vervarcke J, et al. A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. Int J Geriatr Psychiatry. 2000;15(6):506-514.
34. Vigen CL, Mack WJ, Keefe RS, et al. Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. Am J Psychiatry. 2011;168(8):831-839.
35. Madhusoodanan S, Sinha S, Brenner R, Gupta S, Bogunovic O. Use of olanzapine for elderly patients with psychotic disorders: a review. Ann Clin Psychiatry. 2001;13(4):201-213.
36. Solomos K, Geiger O. Olanzapine use in the elderly: a retrospective analysis. Can J Psychiatry. 2000;45(2):151-155.
37. Madhusoodanan S, Brenner R, Alcantra A. Clinical experience with quetiapine in elderly patients with psychotic disorders. J Geriatr Psychiatry Neurol. 2000;13(1):28-32.
38. Kam KY, Jalin AM, Choi YW, et al. Ziprasidone attenuates brain injury after focal cerebral ischemia induced by middle artery occlusion in rats. Prog Neuropsychopharmacol Biol Psychiatry. 2012;39(1):69-74.
39. Rado J, Janicak PG. Aripiprazole for late-life schizophrenia. Clin Interv Aging. 2010;5:253-258.
40. Pigott TA, Carson WH, Sara AR, et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry. 2003;64(9):1048-1056.
41. Madhusoodanan S, Brenner R, Gupta S, Reddy H, Bogunovic O. Clinical experience with aripiprazole treatment in ten elderly patients with schizophrenia or schizoaffective disorder: retrospective case studies. CNS Spectr. 2004;9(11):862-867.
42. Tzimos A, Samokhvalov V, Kramer M, et al. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with 6-month open label extension. Am J Geriatr Psychiatry. 2008;16(1):31-43.
43. Jeste DV, Blazer D, Casey D, et al. ACNP White Paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacol. 2008;33(5):957-970.
44. Wolters EC, Berendse HW. Management of psychosis in Parkinson's disease. Curr Opin Neurol. 2001;14(4):499-504.
45. Tsan JY, Stock EM, Gonzalez JM, et al. Mortality and guideline-concordant care for older patients with schizophrenia: a retrospective longitudinal study. BMC Med. 2012;10:147.
46. Felmet K, Zisook S, Kasckow JW. Elderly patients with schizophrenia and depression: diagnosis and treatment. Clin Schizophr Relat Psychoses. 2011;4(4):239-250.
47. Jeste DV, Maglione JE. Treating older adults with schizophrenia: challenges and opportunities. Schizophr Bull. 2013;39(5):966-968.
48. Kuehn BM. Questionable antipsychotic prescribing remains common, despite serious risks. JAMA. 2010;303(16):1582-1584.
49. Katz R, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M. Comparison of risperidone and placebo for psychosis and behavioral disturbance associated with dementia: a randomized, double-blind trial. J Clin Psychiatry. 1999;60(2):107-115.
50. Lavretsky H, Sultzer D. A structured trial of risperidone for the treatment of agitation in dementia. Am J Geriatr Psychiatry. 1998;6(2): 127-135.
51. Gareri P, Marigliano NM, De Fazio S, et al. Antipsychotics and dementia. BMC Geriatr. 2010;10(Suppl 1):A93.
52. Dorey JM, Beauchet O, Thomas Antérion C, et al. Behavioral and psychological symptoms of dementia and bipolar spectrum disorders: review of the evidence of a relationship and treatment implications. CNS Spectr. 2008;13(9):796-803.
53. Maher AR, Theodore G. Summary of the comparative effectiveness review on off-label use of atypical antipsychotics. J Manag Care Pharm. 2012;18(5 Suppl B):S1-S20.
54. Ballard CG, Gauthier S, Cummings JL, et al. Management of agitation and aggression associated with Alzheimer disease. Nat Rev Neurol. 2009;5(5):245-255.
55. Pelland C, Trudel JF. [Atypical antipsychotic efficacy and safety in managing delirium: a systematic review and critical analysis]. Psychol Neuropsychiatr Vieil. 2009;7(2):109-119.French.
56. Meyers BS, Flint AJ, Rothschild AH, et al. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Arch Gen Psychiatry. 2009;66(8):838-847.
57. Alexopoulos GS. Pharmacotherapy for late-life depression. J Clin Psychiatry. 2011;72(1):e04.
58. Berman RM, Fava M, Thase ME, et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr. 2009;14(4):197-206.
59. Sajatovic M, Coconcea N, Ignacio RV, et al. Aripiprazole therapy in 20 older adults with bipolar disorder: a 12-week, open-label trial. J Clin Psychiatry. 2008;69(1):41-46.
60. Sajatovic M, Calabrese JR, Mullen J. Quetiapine for the treatment of bipolar mania in older adults. Bipolar Disord. 2008;10(6):662-671.
61. Vasudev A, Thomas A. "Bipolar disorder" in the elderly: what's in a name? Maturitas. 2010;66(3):231-235.
62. Aziz R, Lorberg B, Tampi RR. Treatments for late-life bipolar disorder. Am J Geriatr Pharmacother. 2006;4(4):347-364.
63. Newcomer J. Second-generation (atypical) antipsychotic and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(Suppl 1):1-93.
64. Pariente A, Fourrier-Reglat A, Ducruet T, et al. Antipsychotic use and myocardial infarction in older patients with treated dementia. Arch Intern Med. 2012;172(8):648-653.
65. Gill SS, Rochon PA, Herrmann N, et al. A typical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ. 2005;330:445.
66. Citizens Commission on Human Rights. US Food and Drug Administration Warning on Antipsychotic Drugs. California: Citizens Commission on Human Rights; 2005. Available from: http://www.cchrint.org/pdfs/US_Food_and_Drug_Administration_Warnings_on_Antipsychotic_Drugs.pdf. Accessed August 05, 2014.
67. FDA requests boxed warnings on older class of antipsychotic drugs news release. Silver Spring, MD: US Food and Drug Administration; 2008 [updated June 16, 2008; cited June 24, 2008] Available from: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116912.htm. Accessed July 31, 2014.
68. Liperoti R, Onder G, Landi F, et al. All-cause mortality associated with atypical and conventional antipsychotics among nursing home residents with dementia: a retrospective cohort study. J Clin Psychiatry. 2009;70(10):1340-1347.
69. Trifiro G, Gambassi G, Sen EF, et al. Association of community-acquired pneumonia with antipsychotic drug use in elderly patients: a nested case-control study. Ann Intern Med. 2010;152(7):418-425.
70. Liperoti R, Pedone C, Lapane KL, Mor V, Bernabei R, Gambassi G. Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents. Arch Intern Med. 2005;165(22): 2677-2682.
71. Kleijer BC, Heerdink ER, Egberts TC, Jansen PA, van Marum RJ. Antipsychotic drug use and the risk of venous thromboembolism in elderly patients. J Clin Psychopharmacol. 2010;30(5):526-530.
72. Zareba W, Lin DA. Antipsychotic drugs and QT interval prolongation. Psychiatr Q. 2003;74(3):291-306.
73. Glassman AH, Bigger JT Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry. 2001;158(11):1774-1782.
74. Chung AK, Chua SE. Effects on prolongation of Bazett's corrected QT interval of seven second-generation antipsychotics in the treatment of schizophrenia: a meta-analysis. J Psychopharmacol. 2011;25(5): 646-666.
75. Gareri P, De Fazio P, Manfredi VG, De Sarro G. Use and safety of antipsychotics in behavioral disorders in elderly demented people. J Clin Psychopharmacol. 2014;34(1):109-123.
76. Rettenbacher MA, Hofer A, Kemmler G, Fleischhacker WW. Neutropenia induced by second generation antipsychotics: a prospective investigation. Pharmacopsychiatry. 2010;43(2):41-44.
77. Li X, Cameron MD. Potential role of a quetiapine metabolite in quetiapine-induced neutropenia and agranulocytosis. Chem Res Toxicol. 2012;25(5):1004-1011.
78. Baruch Y, Tadger S, Plopski I, Barak Y. Asenapine for elderly bipolar manic patients. J Affect Disord. 2013;145(1):130-132.
79. Correll CU. From receptor pharmacology to improved outcomes: individualizing the selection, dosing, and switching of antipsychotics. Eur Psychiatry. 2010;25(Suppl 2):S12-S21.
80. Ondo WG, Tintner R, Voung KD, Lai D, Ringholz G. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord. 2005;20(8):958-963.
81. Pepersack T, Gilles C, Petrovic M, et al. Prevalence of orthostatic hypotension and relationship with drug use amongst older patients. Acta Clin Belg. 2013;68(2):107-112.
82. Shulman M, Jennifer Njoku I, Manu P. Thrombotic complications of treatment with antipsychotic drugs. Minerva Med. 2013;104(2):175-184.